NASDAQ · Biotechnology

COCP (COCP) Stock

$0.92 +0.14% NASDAQ: COCP Healthcare

Valuation

MetricValue
Price$0.92
Market Cap$12.68M
P/E Ratio-1.46
P/B Ratio1.94
P/S Ratio51.48
EPS (TTM)$0.00
52-Week High$2.67
52-Week Low$0.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-150.00%
ROA-90.00%
ROCE-128.57%
Gross Margin0.00%
Operating Margin0.00%
Net Margin-39.24%
Debt/Equity0.35
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-39.0M$-19.0M$-18.0M$-9.0M
Net Profit$-14.0M$-39.0M$-18.0M$-18.0M$-9.0M
EPS$-1.85$-4.77$0.00$-1.72$-0.78
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$79.0M$41.0M$31.0M$13.0M$10.0M
Total Liabilities$2.0M$1.0M$5.0M$4.0M$3.0M
Cash$59.0M$37.0M$26.0M$10.0M$7.0M
Borrowings$1.0M$0$2.0M$2.0M$2.0M

Latest News

Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer MT Newswires · Jun 3, 2026 Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer GlobeNewswire · Jun 3, 2026 COCP: Presentation Highlights CDI-988 Zacks Small Cap Research · Jun 1, 2026 Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza GlobeNewswire · May 26, 2026 Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results GlobeNewswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-21.0M$-15.0M$-16.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$26.0M$-22.0M$-11.0M$-16.0M$-3.0M
Free Cash Flow$-13.0M$-22.0M$-15.0M$-16.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-67.28%
Quick Ratio2.66
Interest Coverage—
Return 1Y-43.53%
Return 3Y-62.06%
Return 5Y-92.79%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
BRTX $0.20 -2.11% -0.33 $1.83M 0.00%
CING $4.52 -2.59% -1.08 $25.34M 0.00%
DWTX $1.81 +3.14% 1.42 $3.45M 0.00%
EVGNEvogene Ltd. $0.54 -0.04% -0.41 $4.67M 0.00%

About COCP

COCP is led by CEO Sam Lee, employs 11 people, headquartered in US, publicly traded since 2012.

COCP stock trades at $0.92 with a market capitalization of $12.68M. The stock is valued at a price-to-earnings (P/E) ratio of -1.46, price-to-book of 1.94, price-to-sales of 51.48. Over the past 52 weeks the stock has ranged between $0.86 and $2.67, and currently trades 65.5% below its 52-week high.

On profitability, COCP generates a return on equity (ROE) of -150.00%, return on capital employed of -128.57%, an operating margin of 0.00%, a net profit margin of -39.24%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides